vs

Side-by-side financial comparison of IPG PHOTONICS CORP (IPGP) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

IPG PHOTONICS CORP is the larger business by last-quarter revenue ($274.5M vs $207.3M, roughly 1.3× Ultragenyx Pharmaceutical Inc.). IPG PHOTONICS CORP runs the higher net margin — 4.8% vs -62.0%, a 66.9% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 17.1%). IPG PHOTONICS CORP produced more free cash flow last quarter ($10.9M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 4.4%).

IPG Photonics Corporation is a manufacturer of fiber lasers. IPG Photonics developed and commercialized optical fiber lasers, which are used in a variety of applications including materials processing, medical applications and telecommunications. IPG has manufacturing facilities in the United States, Germany, Russia and Italy.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

IPGP vs RARE — Head-to-Head

Bigger by revenue
IPGP
IPGP
1.3× larger
IPGP
$274.5M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+8.8% gap
RARE
25.9%
17.1%
IPGP
Higher net margin
IPGP
IPGP
66.9% more per $
IPGP
4.8%
-62.0%
RARE
More free cash flow
IPGP
IPGP
$111.7M more FCF
IPGP
$10.9M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
4.4%
IPGP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IPGP
IPGP
RARE
RARE
Revenue
$274.5M
$207.3M
Net Profit
$13.3M
$-128.6M
Gross Margin
36.1%
Operating Margin
1.2%
-54.7%
Net Margin
4.8%
-62.0%
Revenue YoY
17.1%
25.9%
Net Profit YoY
69.8%
3.5%
EPS (diluted)
$0.30
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IPGP
IPGP
RARE
RARE
Q4 25
$274.5M
$207.3M
Q3 25
$250.8M
$159.9M
Q2 25
$250.7M
$166.5M
Q1 25
$227.8M
$139.3M
Q4 24
$234.3M
$164.6M
Q3 24
$233.1M
$139.5M
Q2 24
$257.6M
$147.0M
Q1 24
$252.0M
$108.8M
Net Profit
IPGP
IPGP
RARE
RARE
Q4 25
$13.3M
$-128.6M
Q3 25
$7.5M
$-180.4M
Q2 25
$6.6M
$-115.0M
Q1 25
$3.8M
$-151.1M
Q4 24
$7.8M
$-133.2M
Q3 24
$-233.6M
$-133.5M
Q2 24
$20.2M
$-131.6M
Q1 24
$24.1M
$-170.7M
Gross Margin
IPGP
IPGP
RARE
RARE
Q4 25
36.1%
Q3 25
39.5%
Q2 25
37.3%
Q1 25
39.4%
Q4 24
38.6%
Q3 24
23.2%
Q2 24
37.3%
Q1 24
38.7%
Operating Margin
IPGP
IPGP
RARE
RARE
Q4 25
1.2%
-54.7%
Q3 25
3.1%
-106.9%
Q2 25
0.0%
-64.8%
Q1 25
0.8%
-102.6%
Q4 24
6.0%
-74.3%
Q3 24
-108.7%
-94.6%
Q2 24
4.7%
-79.1%
Q1 24
7.6%
-151.9%
Net Margin
IPGP
IPGP
RARE
RARE
Q4 25
4.8%
-62.0%
Q3 25
3.0%
-112.8%
Q2 25
2.6%
-69.0%
Q1 25
1.6%
-108.5%
Q4 24
3.3%
-80.9%
Q3 24
-100.2%
-95.7%
Q2 24
7.8%
-89.5%
Q1 24
9.6%
-156.8%
EPS (diluted)
IPGP
IPGP
RARE
RARE
Q4 25
$0.30
$-1.28
Q3 25
$0.18
$-1.81
Q2 25
$0.16
$-1.17
Q1 25
$0.09
$-1.57
Q4 24
$0.27
$-1.34
Q3 24
$-5.33
$-1.40
Q2 24
$0.45
$-1.52
Q1 24
$0.52
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IPGP
IPGP
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$839.3M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.1B
$-80.0M
Total Assets
$2.4B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IPGP
IPGP
RARE
RARE
Q4 25
$839.3M
$421.0M
Q3 25
$870.4M
$202.5M
Q2 25
$899.6M
$176.3M
Q1 25
$926.9M
$127.1M
Q4 24
$930.2M
$174.0M
Q3 24
$1.0B
$150.6M
Q2 24
$1.1B
$480.7M
Q1 24
$1.1B
$112.3M
Stockholders' Equity
IPGP
IPGP
RARE
RARE
Q4 25
$2.1B
$-80.0M
Q3 25
$2.1B
$9.2M
Q2 25
$2.1B
$151.3M
Q1 25
$2.1B
$144.2M
Q4 24
$2.0B
$255.0M
Q3 24
$2.1B
$346.8M
Q2 24
$2.3B
$432.4M
Q1 24
$2.3B
$140.3M
Total Assets
IPGP
IPGP
RARE
RARE
Q4 25
$2.4B
$1.5B
Q3 25
$2.4B
$1.2B
Q2 25
$2.4B
$1.3B
Q1 25
$2.3B
$1.3B
Q4 24
$2.3B
$1.5B
Q3 24
$2.4B
$1.5B
Q2 24
$2.5B
$1.6B
Q1 24
$2.6B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IPGP
IPGP
RARE
RARE
Operating Cash FlowLast quarter
$28.8M
$-99.8M
Free Cash FlowOCF − Capex
$10.9M
$-100.8M
FCF MarginFCF / Revenue
4.0%
-48.6%
Capex IntensityCapex / Revenue
6.5%
0.5%
Cash ConversionOCF / Net Profit
2.17×
TTM Free Cash FlowTrailing 4 quarters
$-3.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IPGP
IPGP
RARE
RARE
Q4 25
$28.8M
$-99.8M
Q3 25
$35.3M
$-91.4M
Q2 25
$-2.2M
$-108.3M
Q1 25
$13.4M
$-166.5M
Q4 24
$73.8M
$-79.3M
Q3 24
$66.1M
$-67.0M
Q2 24
$53.5M
$-77.0M
Q1 24
$54.6M
$-190.7M
Free Cash Flow
IPGP
IPGP
RARE
RARE
Q4 25
$10.9M
$-100.8M
Q3 25
$14.6M
$-92.7M
Q2 25
$-17.6M
$-110.7M
Q1 25
$-11.4M
$-167.8M
Q4 24
$50.6M
$-79.5M
Q3 24
$43.0M
$-68.6M
Q2 24
$29.2M
$-79.0M
Q1 24
$26.5M
$-193.9M
FCF Margin
IPGP
IPGP
RARE
RARE
Q4 25
4.0%
-48.6%
Q3 25
5.8%
-58.0%
Q2 25
-7.0%
-66.5%
Q1 25
-5.0%
-120.5%
Q4 24
21.6%
-48.3%
Q3 24
18.4%
-49.2%
Q2 24
11.3%
-53.7%
Q1 24
10.5%
-178.2%
Capex Intensity
IPGP
IPGP
RARE
RARE
Q4 25
6.5%
0.5%
Q3 25
8.3%
0.8%
Q2 25
6.1%
1.5%
Q1 25
10.9%
1.0%
Q4 24
9.9%
0.1%
Q3 24
9.9%
1.2%
Q2 24
9.4%
1.4%
Q1 24
11.1%
3.0%
Cash Conversion
IPGP
IPGP
RARE
RARE
Q4 25
2.17×
Q3 25
4.73×
Q2 25
-0.34×
Q1 25
3.58×
Q4 24
9.44×
Q3 24
Q2 24
2.65×
Q1 24
2.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IPGP
IPGP

Materials Processing$232.8M85%
Laser And Non Laser Systems$38.8M14%
Transferred Over Time$5.3M2%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons